Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC)

Trial Profile

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC)

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2016

At a glance

  • Drugs Lurbinectedin (Primary) ; Capecitabine
  • Indications Breast cancer; Colon cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 02 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 11 Oct 2016 Results assessing safety (n=65, cut off April 2016) presented at the 41st European Society for Medical Oncology Congress.
    • 05 Oct 2016 According to a PharmaMar media release, data from this study will be presented at European Society of Medical Oncology (ESMO) congress 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top